Ocular Therapeutix financials
$7.87+2.81%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $13.5M | $10.8M | $13.3M | $14.5M | $13.5M | $10.7M | $17.1M | $15.4M | $16.4M | $14.8M | $14.8M | $15.1M |
| Gross profit | $11.5M | $9.5M | $11.7M | $12.8M | $11.5M | $9.4M | $15.9M | $13.9M | $14.9M | $13.4M | $13.4M | $13.7M |
| Gross margin | 85.1% | 87.7% | 88.0% | 87.8% | 85.6% | 88.2% | 92.8% | 89.9% | 90.8% | 91.0% | 90.6% | 90.9% |
| Operating income | -$82.1M | -$93.3M | -$69.8M | -$68.7M | -$67.6M | -$63.9M | -$50.6M | -$46.0M | -$43.6M | -$31.6M | -$20.1M | -$19.2M |
| Net income | -$78.8M | -$88.6M | -$64.7M | -$69.4M | -$67.8M | -$64.1M | -$48.4M | -$36.5M | -$43.8M | -$64.8M | -$29.2M | -$516.0K |
| Net margin | −584.5% | −821.6% | −488.0% | −477.3% | −503.9% | −598.7% | −283.3% | −236.6% | −266.3% | −438.9% | −197.4% | −3.4% |
| Diluted EPS | $-0.35 | $-0.40 | $-0.29 | $-0.38 | $-0.39 | $-0.38 | $-0.29 | $-0.22 | $-0.26 | $-0.49 | $-0.29 | $-0.25 |
| EBITDA | -$80.3M | -$92.1M | -$68.5M | -$67.6M | -$66.6M | -$62.9M | -$49.6M | -$45.0M | -$42.6M | -$30.7M | -$19.1M | -$18.3M |
| Operating cash flow | -$67.3M | -$66.0M | -$54.2M | -$50.7M | -$55.2M | -$44.7M | -$39.4M | -$36.6M | -$24.8M | -$33.9M | -$22.5M | -$7.7M |
| Free cash flow | -$70.6M | -$70.7M | -$57.1M | -$56.7M | -$56.5M | -$46.6M | -$39.6M | -$36.6M | -$25.5M | -$34.1M | -$22.9M | -$8.0M |
| Diluted shares | 225.0M | 224.1M | 223.1M | 183.9M | 172.6M | 169.4M | 168.2M | 167.0M | 165.8M | 132.0M | 101.8M | 85.1M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $598.6M | $666.7M | $737.1M | $344.8M | $391.1M | $349.7M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $72.8M | $72.1M | $71.3M | $70.6M | $69.9M | $69.2M |
| Total assets | $671.3M | $732.5M | $808.1M | $410.9M | $451.3M | $405.9M |
| Total liabilities | $151.3M | $151.0M | $153.7M | $152.7M | $145.4M | $140.0M |
| Shareholders' equity | $520.0M | $581.6M | $654.3M | $258.2M | $305.9M | $265.9M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology